Inthera Bioscience AG, a Swiss start-up company with a new approach for treating cancer, has received €3.4 million in seed money from a syndicate of venture capital investors led by MS Ventures, the corporate venture arm of Merck KGaA. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
